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Background: Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is an effective rescue therapy for
severe cardiorespiratory failure, but morbidity and mortality are high. We hypothesised that survival decreases with
longer VA ECMO treatment. We examined the Extracorporeal Life Support Organization (ELSO) registry for a
relationship between VA ECMO duration and in-hospital mortality, and covariates including indication for support.
Methods: All VA runs from the ELSO database from 2002 to 2012 were extracted. Multiple runs and non-VA runs were
excluded. Runs were categorized into diagnostic groups. Logistic regression for analysis of the effect of duration on
outcome, and multivariate regression for diagnosis and other baseline factors were performed. Non-linear models
including piecewise logistic models were fitted.
Results: There were 2699 runs analysed over 14,747 days. Logistic regression analysis of the effect of duration
on outcome, and multivariate regression analysis of diagnosis and other baseline factors were performed. In-hospital
survival was 41.4% (95% CI 39.6–43.3). 75% of patients were supported for less than 1 week and 96% for less than
3 weeks. Median duration (4 days IQR 2.0–6.8) was greater in survivors (4.1 (IQR 2.5–6.7) vs 3.8 (IQR 1.7–7.0) p = 0.002).
The final multivariate model demonstrated increasing survival to day 4 (OR 1.53 (95% CI 1.37–1.71) p < 0.001),
decreasing from day 4 to 12 (OR 0.86 (95% CI 0.81–0.91), p < 0.001) with no significant change thereafter (OR
0.98 (95% CI 0.94–1.02), p = 0.400).
Conclusions: ECMO for 4 days or less is associated with higher mortality, likely reflecting early treatment
failure. Survival is highest when patients are weaned on the fourth day of ECMO but likely decreases into the
second week. While this does not suggest weaning at this point will produce better outcomes, it does reflect
the likely time course of ECMO as a bridge in severe shock. Patients with some underlying conditions (like
myocarditis and heart transplantation) achieve better outcomes despite longer support duration. These findings merit
prospective study for the development of prognostic models and weaning strategies.
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Veno-arterial extracorporeal membrane oxygenation (VA
ECMO) is an effective rescue therapy for severe cardiore-
spiratory failure, but morbidity and mortality are high [1].
As opposed to veno-venous (VV ECMO) therapy for se-
vere respiratory failure, VA ECMO provides partial or
complete haemodynamic support in the case of severe
cardiovascular compromise. Use of this treatment modal-
ity is expanding internationally, with increasing numbers
reported in international databases, most notably the
Extracorporeal Life Support Organization (ELSO) registry
with 7850 adult cardiac VA ECMO cases to date, with an
overall survival to discharge of 41% [2].
Prognostic models for survival in VA ECMO treatment
have been developed, such as the survival after veno-
arterial ECMO (SAVE) score [3], based on pre-ECMO
patient and disease factors. As treatment becomes more
sophisticated, and centres have more experience, pro-
longed therapy may become more acceptable and com-
mon. There are some survivors of long-term support [4],
but the relationship between treatment duration and
survival is unclear.
Some cohort studies of mixed VA ECMO patients have
identified similar treatment duration in survivors and non-
survivors on VA ECMO [5]. In terms of other support
types, studies in veno-venous ECMO have found no de-
crease in survival with long-term support [6, 7]. However,
in another study of post-cardiac surgery VA ECMO sup-
port in children the odds of mortality (OR 1.12) increased
per day of treatment [8]. Analysis of children treated with
VA ECMO for more than 14 days in the ELSO registry
showed decreased survival with longer treatment duration
[9]. Given the significant incidence of haemorrhagic,
neurologic and septic complications of therapy, prolonged
therapy may lead to increased mortality, with one analysis
showing significantly increased rates of infection with in-
creased support time [10]. We hypothesised that analysis
of the ELSO registry would identify decreasing survival
with longer runs on VA ECMO.
Given anticipated differences in outcome and treat-
ment duration between medical and post-surgical indica-
tions for ECMO, we hypothesised that the relationship
between duration of ECMO and survival may vary de-
pending on the underlying indication. We examined the
ELSO database for evidence of a relationship between
VA ECMO treatment duration and survival to hospital
discharge. We aimed to examine the effect of available
covariates and interactions with the indication for
ECMO support.
Methods
A retrospective study of the ELSO registry data was con-
ducted. This voluntary database collects baseline data
and outcome data on patients undergoing ECMOtreatment in participating centres, with a total of 232
centres contributing up to 2012 [2]. Data collected in-
clude age, sex, weight, surgical procedures performed,
primary and other diagnoses, discharge location, basic
ventilation data, haemodynamic variables and arterial
blood gas results. All adult VA ECMO runs from the
ELSO database from 2002 to 2012 were extracted. This
excludes paediatric and neonatal patients, patients
undergoing extracorporeal cardiopulmonary resuscita-
tion (E-CPR), and patients on veno-venous (respiratory
support). Multiple runs and non-VA runs were then ex-
cluded. Runs with missing duration data were excluded.
There was no imputation for missing data.
Primary diagnoses were categorised by two reviewers
into predefined post-surgical groups (post-transplant,
post-ventricular assist device (VAD) and other cardiac
surgery), and medical groups (coronary artery disease,
myocarditis, chronic structural, other cardiac and other
non-cardiac). There were 130 ECMO runs without diag-
nostic data.
Treatment duration and other continuous variables
were examined for normality using the Shapiro-Wilk
test, and in particular, treatment duration was found to
be neither normally distributed, nor log-normally dis-
tributed. Normally distributed variables were compared
using the Student t test, while non-normally distributed
variables were compared using the Kruskal-Wallis test.
Categorical variables were examined using the Fisher
exact test. Statistical significance was determined at the
level of p < 0.05.
Survival analysis was then used to examine treatment
duration as a continuous outcome variable. This was
done primarily to examine any pattern in changing sur-
vival with time. Given that two mutually exclusive events
could occur at any time on ECMO (successful weaning
with survival, or death), a competing risks [11] approach
was used to plot these two discontinuation states over
time. Hazard function estimates for survival to hospital
discharge were then examined for a continuous relation-
ship between time on ECMO and probability of survival.
Regression models were then developed to analyse the
effect of treatment duration on survival. Logistic regres-
sion was performed to analyse the effect of treatment
duration on outcome, and multivariate regression was
performed to analyse the effect of diagnostic category
and other baseline factors collected in the ELSO data-
base. Given the non-monotonic nature of the hazard
function demonstrated with survival analysis, non-linear
models were used to model non-linear relationships be-
tween treatment duration and survival. These included
piecewise logistic regression with different break points
for duration near the observed peak of survival, and
polynomials. Piecewise break point selection was per-
formed algorithmically as per Muggeo [12] and with
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survival. Models were compared for maximal goodness
of fit.
In order to fairly compare models in the presence of
missing data for some covariates, the dataset was re-
stricted to the subset of clinically likely meaningful co-
variates (age, sex, weight, time from intubation, arterial
blood gas (ABG) variables, simple haemodynamic vari-
ables, year of treatment and diagnostic category). Ana-
lyses were performed using R software (R Foundation
for Statistical Computing, Vienna, Austria; 2014), includ-
ing the use of the packages cmprsk [13], bshazard and
segmented [12].
Results
In total, 2699 runs over 14,747 days of VA ECMO were
analysed. Summary characteristics of the data are pre-
sented, and compared between groups in Table 1. Overall
survival to hospital discharge was 41.4% (95% CI 39.6–
43.3). The duration of ECMO support varied (0–87 days),
with a long tail of long-term support: 75% of patients were
supported for less than 1 week and 96% were supported
for less than 3 weeks. Median duration (4 days IQR (2.0–
6.8)) was greater in survivors (4.1 (IQR 2.5–6.7) vs 3.8
(IQR 1.7–7.0) p = 0.002). The number of patients treated
increased from 38 in 2002 to 846 in 2012. There was sig-
nificant variation in survival between years ranging from
31.2% in 2005 to 50.9% in 2008 (p = 0.003), but no clear
trend (Fig. 1). The proportion of diagnoses varied between
years, with a trend towards increasing medical indications
(Kendall’s tau 0.477, p = 0.042 for proportion with medical
indications of the total cases per year).
When calculated by day of ECMO discontinuation
(Fig. 2), survival increased from 25.7% on the first day
(95% CI 21.4– 30.5) and peaked on day 4 at 53.6% (95%
CI 48.1–59.0). Hazard function for survival was notTable 1 Baseline characteristics and comparison of survivors and no
Variable Overall
Number of patients 2699
Days of ECMO (median (IQR)) 4.00 (1.96, 6.83)




Weight (kg) (median (IQR)) 75.0 (64.0, 88.9)
Intubation to ECMO (median (IQR))a 10.0 (4.0, 25.0)
pH (median (IQR)) 7.31 (7.21, 7.40)
Bicarbonate (mmol/l) (median (IQR)) 20.0 (16.3, 23.1)
MAP (mmHg) (median (IQR)) 59 (49, 70)
aNumber of hours from endotracheal intubation to initiation of extracorporeal mem
mean arterial blood pressure (MAP) were all measured prior to initiation of ECMO. Iconstant, with a biphasic distribution peaking around
day 7 (Fig. 3). On inspection, survival appeared to de-
crease after this point, but the confidence intervals were
wide due to decreasing numbers of patients at risk.
Univariate logistic regression analysis of the effect of
ECMO duration on survival was best fit using seg-
mented regression with break points at day 4 and day
12. There was no improvement in fit with other break
points or polynomial models. There was increasing sur-
vival per day of ECMO prior to day 4 (odds ratio (OR)
1.39 (95% CI 1.29–1.50), p < 0.001) and then decreasing
survival from day 4 to 12 (OR 0.89 (95% CI 0.86–0.93),
p < 0.001). From day 12 onwards there was no significant
change (OR 0.99 (95% CI 0.96–1.01), p = 0.356).
On multivariate regression analysis with adjustment
for the covariates available there were similar trends
of survival by day, increasing to day 4 (OR 1.53 (95%
CI 1.37–1.71), p < 0.001), and decreasing from day 4
to 12 (OR 0.86 (95% CI 0.81–0.91), p < 0.001) with no
significant change thereafter (OR 0.98 (95% CI 0.94–1.02),
p = 0.400). The significant covariates remaining in the
final model were diagnostic category (p = 0.008), age
(p = <0.001), pH (p = 0.005), mean arterial pressure
(p < 0.001), and time from endotracheal intubation to
initiation of ECMO (p = 0.049).
There were statistically significant differences in sur-
vival (p < 0.001) with better survival in myocarditis
(64.4%) and post-heart transplantation (57.1%), and
poorer survival in other medical cardiac disease (38.4%)
and other surgical cardiac disease (35.9%) (Table 2).
There were also differences in treatment duration by
diagnosis (p < 0.001) with longer duration also in myo-
carditis and heart transplantation, and shorter duration
post VAD. However, there was no significant interaction
between diagnosis and treatment duration in terms of
effect on survival in any model.n-survivors
Died Survived P value
1582 1117
3.83 (1.67, 7.00) 4.13 (2.46, 6.67) 0.002
56.0 (44.0, 65.0) 52.0 (38.0, 61.0) <0.001
0.341
522 (33.0) 340 (30.4)
1048 (66.2) 767 (68.7)
76.0 (63.7, 90.0) 75.0 (64.1, 86.0) 0.138
12.0 (5.0, 31.0) 8.5 (3.0, 22.0) <0.001
7.30 (7.19, 7.39) 7.32 (7.23, 7.40) 0.001
19.2 (15.4, 23.0) 20.6 (17.3, 24.0) <0.001
57 (47, 68) 62 (51, 72) <0.001
brane oxygenation (ECMO). Sex not specified in 22 cases. pH, bicarbonate and
QR interquartile range
Fig. 1 Trends in survival and diagnosis by year of extracorporeal membrane oxygenation (ECMO) treatment. a Survival by year of ECMO
treatment, with total number of patients treated that year, and 95% confidence intervals for survival. b Diagnostic groups by year of ECMO
treatment. VAD ventricular assist device
Fig. 2 Survival by day of extracorporeal membrane oxygenation (ECMO) discontinuation. Errors bars show 95% binomial confidence interval
for survival
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Fig. 3 Estimated survival hazard in the first 4 weeks, with cumulative incidence of survival and mortality. Coloured curves show cumulative
incidence of survival after cessation of extracorporeal membrane oxygenation (ECMO) (green), and mortality after ECMO (red), by duration of
treatment. Instantaneous hazard function estimate for survival plotted in black with 95% confidence interval. Numbers of patients at risk and who
survived or died are shown per week below the chart
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weaned from ECMO but died prior to discharge. The
commonest reason for discontinuation was organ fail-
ure, followed by family request, with similar rates
during treatment (Fig. 4) other than a comparatively
high 7.7% (95% CI 5.3–10.9) mortality rate due to
haemorrhage on day 1.
Discussion
Our analysis of the VA ECMO cases within the ELSO
registry demonstrates that mortality varies with the dur-
ation of ECMO treatment, but in a complex way. We
anticipated that survival would steadily decrease with
treatment duration as progression of disease and treat-
ment complications added to cumulative mortality, as
suggested previously [8]. However, we found thatTable 2 Duration of treatment, overall hospital survival and survival
Overa
confid
Clinical category Number Median
duration (h)
IQR
Medical: non-cardiac 115 87 31–170 49.6%
Medical: other cardiac disease 383 96 48–162 38.4%
Medical: structural heart disease 296 117 58–192 44.3%
Medical: myocarditis 87 154 96–230 64.4%
Medical: coronary artery disease 424 109 51–177 40.1%
Surgical: post VAD 117 68 33–122 41.9%
Surgical: post heart transplantation 175 108 66–173 57.1%
Surgical: other cardiac 972 87 41–146 35.9%
Overall 2699 96 47–164 41.4%
IQR interquartile range, VAD ventricular assist devicesurvival in fact increases in the first few days, peaking
mid-week in the first week of treatment. Inspection of
the estimated survival hazard function and examination
of the regression models fitted suggest that survival de-
creased significantly up to day 12. After this second
change point, there was no evidence of change in sur-
vival (that is, the confidence intervals of the slope in-
cluded zero), or significant change points past this point
that added to model fit.
While this does not provide evidence for a point of
“futility” beyond which treatment has very low survival,
it does provide an insight into the “natural history” of
VA ECMO treatment. In particular, this analysis does
not suggest that weaning should occur on a particular
day in order to maximise survival. Instead, it reflects the
role of ECMO as a bridge, whereby the duration ofby week of ECMO termination
ll survival (95%
ence interval)
Survival at weeks 1, 2 and 3
Week 1 Week 2 Week 3+
(40.6–58.6) 53.5% (43.0–63.7) 42.8% (24.5–63.5) 25.0% (7.1–59.1)
(33.6–43.3) 37.0% (31.7–42.7) 42.0% (31.1–53.8) 47.1% (26.2–69.0)
(38.7–50.0) 43.1% (36.4–50.0) 50.7% (39.3–62.0) 34.8% (18.8–55.1)
(53.9–73.6) 70.6% (57.0–81.3) 62.5% (42.7–78.8) 41.7% (19.3–68.0)
(36.0–45.3) 40.6% (35.3–46.2) 42.2% (32.1–52.9) 35.5% (21.1–53.1)
(33.3–50.9) 41.0% (32.0–50.5) 44.4% (18.9–73.3) 66.7% (20.8–93.9)
(49.7–64.2) 60.0% (51.4–68.0) 52.9% (36.7–68.6) 36.3% (15.2–64.6)
(33.0–39.0) 38.7% (35.3–42.1) 25.3% (19.0–33.0) 20.0% (10.5–34.8)
(39.5–43.3) 42.5% (40.4–44.7) 39.2% (34.9–43.6) 32.9% (26.0–40.6)
Fig. 4 Reasons for discontinuation and death by extracorporeal membrane oxygentation (ECMO) duration. Reasons for discontinuation of ECMO,
and death according to ECMO duration are presented. Colour of bars indicates reason for discontinuation (red organ failure, green family request,
blue diagnosis incompatible with life, purple haemorrhage). Overall outcomes and reasons for discontinuation are summarised
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the underlying disease process. Mortality is especially
high in the first few days, but patients who survive this
period are more likely to then survive when their condi-
tion is such that they are weaned in the first week.
Comparison of reasons for discontinuation in this
early period suggested that fatal haemorrhage was dis-
proportionately represented in the first day of treatment,
whereas organ failure and family request for discontinu-
ation were more evenly spread (Fig. 4). Haemorrhage is
well-documented as a common complication [14] of VA
ECMO treatment that is associated with increased mor-
tality [15], and this suggests that this danger may be
highest in the initiation phase of treatment, at least in
cases of severe illness. However, the commonest reasons
for discontinuation in this early period were still organ
failure and a diagnosis incompatible with life, suggesting
that treatment failure predominates over treatment com-
plications during this phase in non-survivors.
In longer ECMO treatment past one week, survival ap-
pears to decrease again to near the mean survival, with
corresponding relative increases in discontinuation due
to organ failure. After three weeks 96% of patients have
been weaned successfully or have died, and analysis of
data on this “tail” of patients on long-term VA ECMO
did not suggest positive or negative correlation between
treatment duration and survival. This is similar to a re-
cent analysis from the ELSO registry of the survival frac-
tion in prolonged VV ECMO therapy [16]. This may be
due to a balance between increased risk with cumulativeexposure to the risks of disease progression and treatment
complications (for instance intracranial haemorrhage [17]
or infection [10]), and the selection of patients perceived
to be more likely to survive for longer treatment. There is
also an inherent bias in treatment duration based on clin-
ician decision-making due to arbitrary limits on the
amount of time that ECMO is offered. Finally, a trend in
survival of patients on long-term ECMO may not be de-
tected due to the relatively small number of patients
remaining, and consequently insufficient statistical power.
These results are relevant to the clinical application of
VA ECMO, in that they highlight the high mortality rate
in the first few days compared to the relatively good out-
comes in those that can be supported past this point, al-
though it is unlikely that longer runs themselves are the
reason for survival. At the same time, they provide some
support to the use of long-term VA ECMO support, in
that survival does decrease below the overall mean but
does not inevitably have a downward trend with pro-
longed treatment. This is particularly relevant as the use
of ECMO becomes more prevalent, where longer runs
may become more common.
In the dataset analysed there was weak correlation be-
tween more recent years and increased ECMO duration
(Kendall’s tau 0.045, p = 0.001), and certainly increasing
numbers of patients treated for longer than two weeks,
with only 2 of 38 patients in 2002 increasing to 53 of
846 patients in 2012. For example, in recent reports of
increased use of VA ECMO as a “bridge to recovery” in
pulmonary hypertension in the face of organ scarcity,
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and 19.3 days in non-survivors [18].
VA ECMO is also increasingly reported to facilitate
transplantation of “marginal” organs [19], or for novel
indications such as septic shock [20–23]. New ap-
proaches to vascular access may also allow longer ther-
apy; using subclavian access a median duration of 7 days
was reported with advantages in ambulation and vascu-
lar complications [24]. In this dataset, there were larger
numbers of outliers with very long support times in the
more recent year groups in particular. Interestingly, in
one of the largest individual centre datasets comparison
of the first 1000 and second 1000 patients indicated de-
creased support times but correspondingly increased
survival, although there are numerous confounders in
the comparison between the earlier and more recent sets
of patients [25].
Treatment was continued for less than 48 hours in
25.2% (95% CI 23.5–26.8) of patients and the mortality
rate was high (69.7% (95% CI 66.1–73.0)). In Germany
Karagiannidis et al. [26] identified a similarly high mor-
tality rate in a mixed cohort of adults and paediatric pa-
tients, with an even higher incidence (more than one
third) of short VA ECMO treatment times. As was
pointed out in an editorial [27], the key to avoiding these
early mortalities is careful patient selection and avoid-
ance of treatment-related complications. However, an
intervention often instituted as a rescue treatment to
avoid death, will (by definition) have a high early failure
rate. Recognition of this is important to avoid unneces-
sarily prolonged futile treatment.
Patients with myocarditis had the highest survival rate
of 64.4% (95% CI 53.9–73.6) in the medical cohort, but
also the longest treatment times with a median of
154 hours (IQR 96.5–230). This reproduces the results of
similar reports of long support times but good outcomes
in case series of patients with myocarditis supported on
VA ECMO [28–30]. Similarly, amongst post-surgical pa-
tients, those with ECMO after heart transplantation had
the highest survival rate at 57.1% (95% CI 49.7–64.2) and
were supported for a median of 108 hours (IQR 66–173).
These results provide support to other reports of relatively
good survival in this post-transplantation group [31–33],
and in this large dataset the survival was relatively good
despite longer treatment than in other groups.
Furthermore, the lack of any observed interaction be-
tween diagnosis and duration of support suggests that
the natural history of the disease state treated with
ECMO probably influences the baseline hazard rate per
time treated, but that the existence of a relationship be-
tween time treated and mortality is independent of the
indication for support. This may mean that some condi-
tions require shorter or longer periods of time for the
eventual outcome to become clinically apparent.Strengths of this analysis include the very large, inter-
national dataset studied, with a contemporary subset
taken to reflect “modern” VA ECMO practice. This is
larger than any previous analysis of the typical time
course of VA ECMO treatment, and has the largest pub-
lished sample size for adjustment of measured covari-
ates. In addition, treatment time was analysed both in
small time quanta (days), and continuously, by estimat-
ing the instantaneous hazard function. This preserves as
much information about change in mortality rates with
time as possible. Other published analysis of treatment
duration has categorised this into large groups (for in-
stance, more or less than 2 weeks) [6, 9, 34], or com-
pared only mean or median treatment times in survivors
and non-survivors [5, 7].
There are several limitations, principally that while
the dataset is large, it reflects voluntary submission of
data from a variety of different centres with heteroge-
neous practice and case-mix. A registry-based dataset
has the inherent limitation of reflecting the pooled
submitted data of numerous international centres with
different patient populations and different treatment
practices. While partial adjustment for case-mix can
be achieved by examination of baseline measured co-
variates, these results may not reflect outcomes in
any individual unit. Missing data for some baseline
covariates were common, restricting the number of
covariates that could be included, but similar results
for overall effect of treatment duration were seen in
the univariate analysis.
Diagnoses were organised into groups, and this would
result in some groups being more heterogenous than
others, which may limit the applicability of these results
to individual indications for ECMO. However, this is a
compromise in approach between analysing only pooled
data without consideration for diagnosis (which would
maximise sample size), and considering only specific in-
dications in isolated analyses (which would restrict the
intended broad scope of this study). This study did not
attempt to generate a model for individual prognostica-
tion, so a moderate number of diagnostic groups were
chosen to give broad insights into the different trajector-
ies of treatment between indications.
The non-randomised observational nature of these
data limits their applicability in prognostication because
selection and reporting bias may influence the distribu-
tion of reported cases in the database. For instance, very
short runs resulting in treatment failure may be less
likely to be reported, particularly if there is inadequate
time for data collection, while longer runs may be more
likely to be reported. Finally, neurological outcome was
not measured in this dataset, so while associations with
overall survival were analysed, functional outcome could
not be assessed as a secondary outcome.
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Survival in VA ECMO treatment varies with treatment dur-
ation, indication for treatment and other patient factors. In
the early phase, survival increases per day such that 4 days
or less on VA ECMO is associated with a significantly
higher mortality rate, most likely reflecting early treatment
failure. Survival was observed to be highest when weaned
on the fourth day of ECMO but it likely decreases into the
second week. Relatively constant survival was observed
after this point. While there are survivors of long-term
treatment, three quarters of patients receive ECMO for less
than one week. Some patients with underlying conditions
(like myocarditis and heart transplantation) achieve better
outcomes despite longer support duration. While this can-
not guide prognostication in individual patients, it is rele-
vant when considering the likely required duration of
therapy in different settings. These findings merit further
prospective studies for the development of additional prog-
nostic models and weaning strategies.
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